Respiratory syncytial virus is the second most common cause of infant mortality and a major
cause of morbidity and mortality in older adults (aged> 60 years). Efforts to develop a …

Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

Background Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract
infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV …

Background The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract …

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among US infants.
In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting …

Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …

Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …

Background In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-
life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants …

Nirsevimab for Prevention of RSV Nirsevimab is a monoclonal antibody targeting respiratory
syncytial virus. In this trial, the safety of nirsevimab was assessed in infants eligible to …

Respiratory syncytial virus (RSV) causes a spectrum of respiratory illnesses in infants and
young children that may lead to hospitalizations and a substantial number of outpatient …